Open Nav

New Horizons Pharma

To obtain funding for further ALDH2 enzyme development

  • Date:Thursday, October 18
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:New Horizons Pharma is a start-up company specialized on the development of innovative medical treatments for four serious medical conditions related to acute alcohol consumption: alcohol poisoning, alcohol-disulfiram reaction, disulfiram like reaction and Asian flush as well as ischemia-reperfusion injury such as myocardial Infarction. All these life threatening conditions associated with temporary ALDH2 enzyme deficiency and can be treated through IV administration of ALDH2 in an emergency room. This treatment would quickly decrease levels of toxic metabolites in the blood and, thus, prevent severe organ toxicity.
  • Company Website:
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:Delaware                    
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :Human recombination ALDH2 enzyme
  • Development Phase of Primary Product:Pre-Clinical
  • Previous and Current Investors:Angel
  • Total Amount Raised to Date, In All Rounds:$150,000,00
Ilana Katsnelson
New Horizons Pharma